Is Adaptive Biotechnologies a Buy?

There's nothing like a viral pandemic to remind investors how important it is to understand the human immune system. Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared when the biotech took steps to address the coronavirus pandemic and partnered with Amgen (NASDAQ: AMGN) and Microsoft (NASDAQ: MSFT) in the process.

Earlier this year, an enthusiastic market more than doubled the price of Adaptive Biotechnologies stock. Now that shares are trading around 22% below their recent peak, investors are wondering if it's a good time to buy.

Image source: Getty Images.

Continue reading

Source Fool.com